CV Farzin Farzaneh D.Phil., FRCPath., FRSB
Professor of Molecular Medicine, King’s College London
Date of Birth: 19 August 19, 1953 – Tehran, Iran
Education:
1970 Completion of High School studies (GCSE Examinations) in UK 1973/75 Higher National Diploma at Brighton College of Technology.
1975/76 BSc Developmental Biology, University of Aberdeen.
1976/77 MSc in Biochemistry, University of Aberdeen.
1977/79 PhD in Cell & Molecular Biology, University of Sussex.
Fellowships:
1979/82 Beit Memorial Fellowship, University of Sussex. 1983 EMBO Fellowship, University of Amsterdam 1984 MRC Fellowships, University of Sussex.
Academic positions:
1985 Lecturer, King's College London (KCL)
1986-1993 Founded Molecular Genetics Unit, appointed to Senior Lectureship at KCL.
1993-2004 Appointed founding Head of Department of Molecular Medicine, KCL.
1996 - Personal Chair in Molecular Medicine.
2004 - Honorary Consultant in Molecular Medicine, Department of Haematological Medicine, King’s College Hospital NHS Trust, London.
- Honorary Consultant, Qualified Person, at the Institute of Child Health, and the
Great Ormond Street Hospital NHS Trust
- Qualified Person, BRC GMP Facility at Guy’s & St Thomas’ Hospital NHS Trust
10 most sited publications (>250 Papers with an average of >29 citations each):
- Tye GJ, Ioannou K, Amofah E, Quartey-Papafio R, Westrop SJ, Krishnamurthy K, Noble A, Harrison PM, Gaensler KML, Barber LD, Farzaneh F (2015). The combined molecular adjuvant CASAC enhances the CD8+ T cell response to a tumor-associated self-antigen in aged, immunosenescent mice. Immunity & Ageing 12:6 doi:10.1186/s12979-015-0033-0
- Oppenheim D, Spreafico R, Etuk A, Malone D, Amofah E, Peña-Murillo C, Murray T,
McLaughlin L, SC Beak, Allan S, Belousov A, Passioukov A, Gerdes C, Umaña P, Farzaneh F, Ross PJ (2014). Glyco-engineered anti-EGFR mAb elicits ADCC by NK cells from colorectal cancer patients irrespective of chemotherapy. Br J Cancer. 110 (5): 1221-1227.
- Williams GT, Farzaneh F (2012). Are snoRNAs and snoRNA host genes new players in cancer? Nature Reviews Cancer 12(2): 84-8.
- Hardwick N, Chan L, Ingram W, Mufti G, Farzaneh F (2010). Lytic activity against primary AML cells is stimulated in vitro by an autologous whole cell vaccine expressing IL-2 and CD80. Cancer Immunol Immunother. 59(3): 379-388.
- Ingram W, Chan L, Guven H, Darling D, Kordasti S, Hardwick N, Barber L, Mufti GJ, Farzaneh F (2009). Human CD80/IL-2 lentivirus transduced acute myeloid leukaemia (AML) cells promote natural killer (NK) cell activation and cytolytic activity: implications for immunotherapy. Brit. J. Haematol. 145(6): 749-60.
- McKie AT, Barrow D, Latunde-Dada GO, Rolfs A, Sager G, Mudaly E, Mudaly M, Richardson C, Barlow D, Bomford A, Peters TJ, Raja KB, Shirali S, Hediger MA, Farzaneh F, Simpson RJ (2001). Iron-regulated ferric reductase associated with the absorption of dietary iron. Science 291: 1755-1759.
- Galea-Lauri J, Darling D, Kuiper M, Gäken J, Souberbielle B & Farzaneh F (1999). Expression of a variant CD28 on a sub-population of human NK cells: Implications for B7mediated stimulation of NK cells. J. Immunology 163: 62-70.
- Gäken JA, Tavassoli M, Gan SU, Vallian S, Giddings I, Darling DC, Thomas MG, Schreiber V, Menissier-de Murcia J, Collins MKL, Shall S, Farzaneh F (1996). Efficient retroviral infection of mammalian cells requires poly(ADP-ribose) polymerase activity. J. Virol 70; 3992-4000.
- Harrison PM, Frezner Degen SJ, Williams R, Farzaneh F (1994). Hepatic expression of heptocyte-growth-factor/macrophage-stimulating protein mRNA in fulminant hepatic failure. Lancet 344; 27-28.
- Farzaneh F, Zalin R, Brill D, Shall S (1982). DNA strand breaks and ADP-ribosyl transferase activation during cell differentiation. Nature 300; 362-366.
Two edited books on the “The Human Genome: A Functional Analysis” and “Gene Therapy of Cancer”.
List of Major grants received in the last five years
|
Funding Source
|
Project title
|
Coordinator
|
Duration
|
Total funding
|
2010
|
Roche
Pharmaceuticals.
|
Analysis of NK cell biology and and induction of ADCC pre-cvlinical and clinical studies
|
F Farzaneh
|
2010/2014
|
£2,553,000
|
2013
|
BBSRC
|
Biotechnology and Biological Sciences Research Council (BBSRC). Development of an enhanced gene specific technology for the isolation of protein binding at a single locus in vivo.
|
F Farzaneh, K Ford
|
2013/2015
|
£120,000
|
2012
|
Northwest
BioTherapeutics
(NWBT)
|
DCVax for glioblastoma.
|
F Farzaneh
|
2012/2017
|
£2,966,000
|
2012
|
Department of
Health UK
|
Department of Health Core Support for Cell & Gene Therapy GMP
Facility
|
F. Farzaneh
|
2012/2017
|
£600,000
|
2013
|
Leukaemia
Lymphoma
Research
(Bloodwise)
|
Pre-emptive immune therapy to prevent relapse of myeloid malignancies. PIs: Farzin Farzaneh & Linda Barber.
|
F Farzaaneh & L Barber
|
2013/2017
|
£1,093,000
|
2014
|
Cellectis
Pharmaceuticals
|
Manufacture of lentivirus vectors for allogeneic CAR cell therapy
|
F Farzaneh
|
2014/2016
|
£1,800,000
|
2015
|
BBSRC/EPSRC/IB
Catalyst
|
Large-scale lentiviral vector production.
|
F Farzaneh
& Lucas
Chan
|
2015/2018
|
£731,000
|
2015
|
I4I, Department of Health (NIHR)
|
Next generation CAR19 studies.
|
F Farzaneh
|
2015/2019
|
£959,000
|
2015
|
Auolus
Pharmaceuticals
|
Development of a novel procedure for the rapid manufacture of retroviral vectors.
|
F Farzaneh
|
2015/2016
|
£900,000
|
2016
|
Cell & Gene
Therapy Catapult
|
Development of viral vector industrialisation processes.
|
F Farzaneh
|
2016/2017
|
£130,000
|
2016
|
Cellectis
Pharmaceuticals
|
Development of lentivirus vectors.
|
F Farzaneh
|
2016/2019
|
£10,300,000
|
Total
|
|
|
|
|
£22,967,000
|
|